References
- Abete I, Goyenechea E, Zulet MA, Martínez JA. (2011). Obesity and metabolic syndrome: Potential benefit from specific nutritional components. Nutr Metab Cardiovasc Dis, 21 Suppl 2, B1–15.
- Aggarwal BB, Bhardwaj A, Aggarwal RS, Seeram NP, Shishodia S, Takada Y. (2004). Role of resveratrol in prevention and therapy of cancer: Preclinical and clinical studies. Anticancer Res, 24, 2783–2840.
- Baile CA, Yang JY, Rayalam S, Hartzell DL, Lai CY, Andersen C, Della-Fera MA. (2011). Effect of resveratrol on fat mobilization. Ann N Y Acad Sci, 1215, 40–47.
- Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, Prabhu VV, Allard JS, Lopez-Lluch G, Lewis K, Pistell PJ, Poosala S, Becker KG, Boss O, Gwinn D, Wang M, Ramaswamy S, Fishbein KW, Spencer RG, Lakatta EG, Le Couteur D, Shaw RJ, Navas P, Puigserver P, Ingram DK, de Cabo R, Sinclair DA. (2006). Resveratrol improves health and survival of mice on a high-calorie diet. Nature, 444, 337–342.
- Chen J. (2011). Multiple signal pathways in obesity-associated cancer. Obes Rev, 12, 1063–1070.
- Choi SY, Kim S, Son D, Lee P, Lee J, Lee S, Kim DS, Park Y, Kim SY. (2007). Protective effect of (4-methoxybenzylidene)-(3-methoxynophenyl)amine against neuronal cell death induced by oxygen and glucose deprivation in rat organotypic hippocampal slice culture. Biol Pharm Bull, 30, 189–192.
- Clapham JC, Arch JR. (2011). Targeting thermogenesis and related pathways in anti-obesity drug discovery. Pharmacol Ther, 131, 295–308.
- de la Lastra CA, Villegas I. (2007). Resveratrol as an antioxidant and pro-oxidant agent: Mechanisms and clinical implications. Biochem Soc Trans, 35, 1156–1160.
- García Díaz E, Martín Folgueras T. (2011). Systematic review of the clinical efficacy of sibutramine and orlistat in weight loss, quality of life and its adverse effects in obese adolescents. Nutr Hosp, 26, 451–457.
- Ghanizadeh A. (2008). Sertraline-associated hair loss. J Drugs Dermatol, 7, 693–694.
- Kim S, Ko H, Park JE, Jung S, Lee SK, Chun YJ. (2002). Design, synthesis, and discovery of novel trans-stilbene analogues as potent and selective human cytochrome P450 1B1 inhibitors. J Med Chem, 45, 160–164.
- Kreuz S, Schoelch C, Thomas L, Rist W, Rippmann JF, Neubauer H. (2009). Acetyl-CoA carboxylases 1 and 2 show distinct expression patterns in rats and humans and alterations in obesity and diabetes. Diabetes Metab Res Rev, 25, 577–586.
- Petrovski G, Gurusamy N, Das DK. (2011). Resveratrol in cardiovascular health and disease. Ann N Y Acad Sci, 1215, 22–33.
- Rayalam S, Yang JY, Ambati S, Della-Fera MA, Baile CA. (2008). Resveratrol induces apoptosis and inhibits adipogenesis in 3T3-L1 adipocytes. Phytother Res, 22, 1367–1371.
- Rhéaume C, Leblanc MÈ, Poirier P. (2011). Adiposity assessment: explaining the association between obesity, hypertension and stroke. Expert Rev Cardiovasc Ther, 9, 1557–1564.
- Shin NH, Ryu SY, Choi EJ, Kang SH, Chang IM, Min KR, Kim Y. (1998). Oxyresveratrol as the potent inhibitor on dopa oxidase activity of mushroom tyrosinase. Biochem Biophys Res Commun, 243, 801–803.
- Szkudelska K, Szkudelski T. (2010). Resveratrol, obesity and diabetes. Eur J Pharmacol, 635, 1–8.
- Tabak F, Gunduz F, Tahan V, Tabak O, Ozaras R. (2009). Sertraline hepatotoxicity: Report of a case and review of the literature. Dig Dis Sci, 54, 1589–1591.
- Tong I. (2005). Acetyl-coenzyme A carboxylase: Crucial metabolic enzyme and attractive target for drug discovery. Cell Mol Life Sci, 62, 1784–1803.
- Wakil SJ, Abu-Elheiga LA. (2009). Fatty acid metabolism: Target for metabolic syndrome. J Lipid Res, 50 Suppl, S138–S143.
- Walle T. (2011). Bioavailability of resveratrol. Ann N Y Acad Sci, 1215, 9–15.
- Wannamethee SG, Shaper AG, Whincup PH, Lennon L, Sattar N. (2011). Obesity and risk of incident heart failure in older men with and without pre-existing coronary heart disease: Does leptin have a role? J Am Coll Cardiol, 58, 1870–1877.
- Wenzel E, Somoza V. (2005). Metabolism and bioavailability of trans-resveratrol. Mol Nutr Food Res, 49, 472–481.